OverviewSuggest Edit

Abeona Therapeutics is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

TypePublic
Founded2013
HQDallas, TX, US
Websiteabeonatherapeutics.com
Overall CultureA+

Latest Updates

Employees (est.) (Mar 2020)88(+7%)
Job Openings5
Revenue (FY, 2020)$10 M(+234%)
Share Price (May 2021)$1.5(-24%)
Cybersecurity ratingAMore

Key People/Management at Abeona Therapeutics

Steven H. Rouhandeh

Steven H. Rouhandeh

Chairman of the Board
Jay Bircher

Jay Bircher

Chief Technical Officer
Michael Amoroso

Michael Amoroso

President, Chief Executive Officer
Todd Wider

Todd Wider

Director
Christine Silverstein

Christine Silverstein

Director
Edward Carr

Edward Carr

Chief Accounting Officer, Principal Financial Officer
Show more

Abeona Therapeutics Office Locations

Abeona Therapeutics has offices in Dallas, Cleveland, New York and Madrid
Dallas, TX, US (HQ)
3333 Lee Pkwy #600
Cleveland, OH, US
6555 Carnegie Ave 4th floor
New York, NY, US
1330 6th Ave 33rd Floor
Madrid, ES
Av. de Manoteras, 30a
Show all (4)

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Revenue

Abeona Therapeutics's revenue was reported to be $10 m in FY, 2020
USD

Revenue (FY, 2020)

10.0m

Net income (FY, 2020)

(84.2m)

EBIT (FY, 2020)

(81.4m)

Market capitalization (7-May-2021)

152.5m

Closing stock price (7-May-2021)

1.5

Cash (31-Dec-2020)

12.6m

EV

148.7m
Abeona Therapeutics's current market capitalization is $152.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

837.0k3.0m10.0m

Revenue growth, %

258%

General and administrative expense

10.9m20.1m20.7m23.8m

R&D expense

17.0m38.7m48.6m30.1m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

186.0k217.0k219.0k2.6m819.0k1.7m

General and administrative expense

3.0m2.6m2.2m2.9m4.6m5.0m5.7m5.6m4.7m6.4m5.5m

R&D expense

2.2m5.8m3.3m8.2m7.9m13.2m11.7m16.3m10.9m6.8m6.1m

Operating expense total

5.5m8.7m5.6m11.2m12.8m18.6m19.1m24.0m17.6m46.1m11.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

137.8m18.8m129.3m12.6m

Accounts Receivable

107.0k81.0k

Prepaid Expenses

2.7m3.8m3.1m2.7m

Current Assets

140.6m88.9m132.4m97.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

63.2m58.3m56.5m132.0m50.0m33.6m25.9m42.6m47.9m40.2m14.5m

Accounts Receivable

148.0k97.0k111.0k64.0k47.0k352.0k38.0k40.0k15.0k

Prepaid Expenses

463.0k867.0k1.8m2.1m1.9m2.0m3.4m2.3m1.7m2.7m924.0k

Current Assets

63.8m59.3m58.4m134.2m121.8m114.6m71.7m64.9m49.6m118.8m108.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.3m)(56.7m)(76.3m)(84.2m)

Depreciation and Amortization

741.0k2.4m7.8m4.6m

Accounts Payable

(1.3m)7.7m(1.7m)

Cash From Operating Activities

(22.9m)(39.1m)(62.8m)(35.0m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.2m)(13.5m)(18.9m)(8.5m)(20.2m)(36.6m)(18.6m)(42.5m)(59.9m)(48.2m)(61.2m)

Depreciation and Amortization

250.0k457.0k595.0k174.0k464.0k969.0k1.7m3.7m5.7m2.1m2.9m

Accounts Payable

(2.2m)(77.0k)(1.7m)3.5m3.4m7.9m(910.0k)3.0m(2.5m)

Cash From Operating Activities

(5.9m)(10.8m)(17.6m)(4.1m)(13.1m)(22.1m)(15.1m)(30.3m)(48.6m)(13.2m)(22.7m)
USDQ1, 2017

Revenue/Employee

9.8k

Financial Leverage

1.1 x
Show all financial metrics

Abeona Therapeutics Operating Metrics

FY, 2018FY, 2019

Product Candidates

88

Facility Space, sq. ft.

55.8 k57.4 k

Manufacturing Space, sq. ft.

43.7 k45.3 k
Show all operating metrics

Abeona Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Abeona Therapeutics LLCMay 15, 2015
MacroChem CorporationFebruary 25, 2009
Somanta Pharmaceuticals, Inc.January 04, 2008
Abeona Therapeutics Europe, S.L.
Virium Pharmaceuticals, Inc.

Abeona Therapeutics Revenue Breakdown

Embed Graph

Abeona Therapeutics revenue breakdown by business segment: 6.7% from Royalties and 93.3% from Foundation Revenues

Abeona Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Abeona Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Abeona Therapeutics Online and Social Media Presence

Embed Graph

Abeona Therapeutics Company Culture

  • Overall Culture

    A+

    94/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A

    89/100

Learn more on Comparably

Abeona Therapeutics News and Updates

Thinking about buying stock in Motus GI, Abeona Therapeutics, Skillz Inc, Marker Therapeutics, or Nikola Corp?

NEW YORK, April 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MOTS, ABEO, SKLZ, MRKR, and NKLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting

NEW YORK and CLEVELAND, April 20, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association for Research in Vis…

Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors

New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products

Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors

Refreshed board to bring fresh perspectives, relevant expertise and diverse experience Refreshed board to bring fresh perspectives, relevant expertise and diverse experience

Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer

CEO appointment provides continuity and reflects company’s demonstrated strong operational performance CEO appointment provides continuity and reflects company’s demonstrated strong operational performance

Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 …
Show more

Abeona Therapeutics Blogs

New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy

In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects In addition, ABO-102 and A…

Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™

NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interim results from its ABO-102 Phase 1/2 Transpher A study for MPS IIIA and ABO-101 Phase 1/2 Transp…

Abeona Therapeutics Reports Third Quarter Financial Results

Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third quarter 2020 and recent b…

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC Retained as Financial Advisor to Assist with the Review of Strategic Options NEW YORK and CLEVELAND, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene…

Abeona Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participate in the following upcoming investor conferences. João Siffert, M.D., Chief Executive Officer, …

Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease

NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced tha…
Show more

Abeona Therapeutics Frequently Asked Questions

  • When was Abeona Therapeutics founded?

    Abeona Therapeutics was founded in 2013.

  • Who are Abeona Therapeutics key executives?

    Abeona Therapeutics's key executives are Steven H. Rouhandeh, Jay Bircher and Michael Amoroso.

  • How many employees does Abeona Therapeutics have?

    Abeona Therapeutics has 88 employees.

  • What is Abeona Therapeutics revenue?

    Latest Abeona Therapeutics annual revenue is $10 m.

  • What is Abeona Therapeutics revenue per employee?

    Latest Abeona Therapeutics revenue per employee is $113.6 k.

  • Who are Abeona Therapeutics competitors?

    Competitors of Abeona Therapeutics include CSL Behring, Advance Medical and Pure Life Renal.

  • Where is Abeona Therapeutics headquarters?

    Abeona Therapeutics headquarters is located at 3333 Lee Pkwy #600, Dallas.

  • Where are Abeona Therapeutics offices?

    Abeona Therapeutics has offices in Dallas, Cleveland, New York and Madrid.

  • How many offices does Abeona Therapeutics have?

    Abeona Therapeutics has 4 offices.